5 Key Takeaways | Best Practices in Patent Drafting: Addressing 112 and Enablement after Amgen
Nature of the Case and Issue(s) Presented: Myrbetriq is a drug used to treat overactive bladder. It utilizes a hydrogel-based sustained-release oral tablet formulation to control the rate at which the active ingredient,...more
The Federal Circuit recently reversed a district court decision that found a patent that did not describe after-arising technology failed to satisfy the written description requirement. In so doing, the Federal Circuit...more